human ifn-gamma r1/cd119 antibody  (Bio-Techne corporation)

Journal: iScience

Article Title: Distinct CD8 + T cell types associated with COVID-19 severity in unvaccinated HLA-A2 + patients

doi: 10.1016/j.isci.2026.115880

Figure Lengend Snippet: Information on 11 selected HLA-A2-binding 9-mer peptides derived from the SARS-CoV-2 genome (A) Workflow of HLA-A2-binding peptide prediction with NETMHCpan4.1 and IFN-γ ELISpot assay of PBMCs from 24 patients with COVID-19 using 31 predicted peptides ( and ). (B) Homology of 11 selected peptides among SARS-CoV-2 variants and other strains (as indicated). “YES” indicates that more than 90% of epitope sequences matched within 200 selected peptide sequences from the database . Otherwise, the % of matched sequences is shown. “NO” indicates no matched sequences. (C) Information on the SARS-CoV-2 genome and mapping of 11 selected peptides on its genome.

Article Snippet: anti-human-IFN-γ antibody , MABTECH , Cat# 3420-3-250; RRID: AB_907283.

Techniques: Binding Assay, Derivative Assay, Enzyme-linked Immunospot

Journal: iScience

Article Title: Distinct CD8 + T cell types associated with COVID-19 severity in unvaccinated HLA-A2 + patients

doi: 10.1016/j.isci.2026.115880

Figure Lengend Snippet: IFN-γ ELISpot of CD8 + T cells in PBMCs from HLA-A2 + patients with COVID-19 using selected SARS-CoV-2 peptides (A) Cross-sectional ELISpot assay of HLA-A2-restricted CD8 + T cell responses against 11 selected peptides in PBMCs from 26 patients with mild, 8 with moderate, and 8 with severe COVID-19, respectively. (B) Log10-transformed mean spot-forming cell (SFC) counts (log10[Mean SFC +1]) per patient across 11 peptides in patients with mild, moderate, and severe COVID-19. Each point represents the mean response for one patient across 11 peptides ( n = 42 patients). A +1 pseudocount is added before the log10 transformation to accommodate zero values. Statistical comparisons were performed using a negative binomial mixed-effects model with Holm-Bonferroni correction for multiple comparisons. NS: not significant. (C) Longitudinal ELISpot assay of HLA-A2-restricted CD8 + T cell responses against selected peptides in PBMCs from patients with mild and moderate COVID-19 (as indicated).

Article Snippet: anti-human-IFN-γ antibody , MABTECH , Cat# 3420-3-250; RRID: AB_907283.

Techniques: Enzyme-linked Immunospot, Transformation Assay